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Abstract 
Chemotherapy-induced diarrhoea (CID) is a common side-effect experienced by patients being 
treated with a variety of antineoplastic agents. Approximately 80% of patients undergoing che-
motherapeutic treatment for colorectal and other gastrointestinal cancers present with CID; 
moreover, about 5% of early deaths associated with combination anti-cancer chemotherapy are 
due to CID. Chronic post-treatment diarrhoea amongst cancer survivors can persist for more than 
10 years greatly effecting long-term quality of life. Gastrointestinal toxicities such as diarrhoea 
and vomiting are amongst the primary contributors to dose reductions and delays throughout 
anti-cancer treatment, presenting a significant hurdle in clinical management of anti-cancer re-
gimes and often result in sub-optimum treatment. However, little is known about pathophysi- 
ological mechanisms underlying CID. This work provides a review of chemotherapy-induced di-
arrhoea, current management guidelines, and shortcomings of current treatments as well as 
emerging and already existing anti-diarrhoeal treatments potentially suitable for CID. 
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1. Introduction 
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the western world [1] [2]. 
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With global incidence and mortality rates of approximately 1.2 million and 610,000 respectively per year [3], 
and consequently low 5 and 10 year survival rates, CRC is projected to account for more than 1.6 million deaths 
annually by 2020 [4], placing it amongst the highest contributors to cancer related deaths globally [3] [5]-[7]. 
Surgical resection of the tumour-bearing and adjacent segments of intestines is used in an attempt to eliminate 
all cancer cells. However, about half of patients are diagnosed beyond stage III, where penetration of the intes-
tinal wall and metastasis to surrounding tissues have already occurred; therefore, chemotherapeutic intervention 
has been implemented as a mainstream adjuvant therapy, broadening the avenues of treatment [7] [8]. 
Advances in medicine over the last 50 years have widened the prospects of CRC treatment allowing it to be 
approached and administered in a variety of ways. Surgical resection, radiotherapy and/or chemotherapy de-
pending on the location of tumour may now be combined and tailored for targeted treatment. Furthermore, 
chemotherapeutics may be manipulated and modified to be delivered as adjuvants, to compliment and/or im-
prove the efficacy of an already delivered drug, as well as being delivered in combination, merging two or more 
chemotherapeutic agents in a single infusion. 
Current combinations of chemotherapeutic agents include 5-fluorouracil (5-FU)/leucovorin with oxaliplatin 
(FOLFOX), 5-FU/leucovorin and irinotecan (FOLFIRI), capecitabine and oxaliplatin (CAPEOX/XELOX) and 
5-FU/leucovorin/oxaliplatin and irinotecan (FOLFOXIRI) [9]-[11]. Several key trials undertaken in 2000 estab-
lished improved efficacy of FOLFOX and FOLFIRI combinations in metastatic CRC. As a result, FOLFOX and 
FOLFIRI have become the standard of care throughout most of the world, showing moderate superiority when 
compared to previous chemo-doublet 5-FU/LV, promoting higher overall survival rates and progression-free 
survival by approximately 12 months. Although proven to be effective in the treatment of CRC, with mortality 
rates decreasing by approximately 50% in most parts of the world since 1950 [12]-[14], these cytotoxic chemo-
therapies are notorious for prompting undesirable neurological and gastrointestinal side-effects (Table 1). 
Chronic side-effects often result in dose limitations, and in severe circumstances cessation of anti-cancer 
treatment, presenting a constant challenge in efficient and tolerable treatment of CRC [15]-[21]. Amongst the 
most common of these dose-limiting side-effects is chemotherapy-induced diarrhoea (CID) affecting approxi-
mately 80% of patients undergoing chemotherapeutic treatment for colorectal and other gastrointestinal cancers 
[20] [22]. Moreover, about 5% of early deaths associated with combination anti-cancer chemotherapy are due to 
CID [23]. Although there are now established and well-structured guidelines to navigate management of CID, 
numerous attempts to prevent peripheral and gastrointestinal neurotoxicity have proven ineffective thus far [18] 
and avenues of treatment are still limited and carry an excessive amount of side-effects including worsening of 
already chronic gastrointestinal symptoms. 
Investigation of the mechanisms underlying adverse effects caused by anti-cancer treatment is imperative for 
the development of new therapies to target such pathologies as CID, to increase effectiveness of current treat-
ments and improve CRC patients’ quality of life. 
2. Chemotherapy-Induced Diarrhoea 
About 40% of patients receiving standard dose chemotherapy and all patients receiving high dose chemotherapy 
for gastrointestinal cancers exhibit pain, ulceration, bloating, vomiting and diarrhoea [30] [31]. Recent statistics 
on colorectal cancer and its treatments indicate that CID occurs at rates as high as 80% in patients [32]. Diar-
rhoea is a frequently under-recognised clinical hurdle that significantly affects morbidity and mortality of cancer 
 
Table 1. Neurotoxic and gastrointestinal side-effects associated with anti-cancer chemotherapeutic agents used for the treat-
ment of CRC [24]-[29]. 
Drug Side-effects 
Carboplatin Cortical blindness, peripheral sensory neuropathy, nausea, vomiting, constipation and diarrhoea. 
Cisplatin Encephalopathy, headache, stroke, seizures, sensory peripheral neuropathy, Lhermitte’s sign, muscle cramps, nausea, vomiting and diarrhoea. 
Oxaliplatin Paraesthesia, sensory peripheral neuropathy, nausea, vomiting, weight loss, constipation and diarrhoea. 
5-Fluorouracil Cerebellar dysfunction, inflammatory leukoencephalopathy, peripheral neuropathy, nausea, vomiting, severe diarrhoea and anorexia. 
Irinotecan Dysarthria, peripheral sensory neuropathy, palmar-plant erythrodysthesia, nausea, vomiting, severe diarrhoea, constipation and anorexia. 
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patients worldwide [22]. Chemotherapeutic agents most commonly associated with CID include 5-FU, capecit-
abine, irinotecan and oxaliplatin [32] [33]. Although prevalence and severity of chemotherapy-induced diar-
rhoea varies greatly based on the combination of chemotherapeutics, certain regimens, especially those contain-
ing 5-FU in combination with irinotecan are associated with rates as high as 87% [22] [34] with one third of pa-
tients experiencing severe (grade 3 or 4) (Table 2) diarrhoea [35]. 
Though CID is a clearly established side-effect of gastrointestinal cancer treatment, little research is underway 
to determine its underlying mechanisms. CID is believed to be a form, or by-product, of alimentary mucositis; 
that is, inflammation and ulceration of the mucous membranes of the digestive tract [37]. Alimentary mucositis 
occurs as a result of altered intestinal microflora and mucin secretion, and is a highly probable contributor to the 
development of CID; however the pathophysiology behind CID is extensive and complex and probably results 
from several overlapping mechanisms [37]. 
Specific anti-cancer treatments can be directly linked to a variety of different types of diarrhoea including 
secretory, osmotic, malabsorptive, exudative, motility related and inflammatory; all of which may be differen-
tially diagnosed from varying symptomology [37]. 
Disruption to water and electrolyte balance within the gastrointestinal tract is a key component in the patho-
physiology of all types of diarrhoea. Intestinal water balance involves many complex processes and pathways 
involving inflammatory mediators, hormones and neuropeptides that are strictly regulated to maintain the integ-
rity of the intestinal wall, efficiency of the circulatory and enteric nervous systems [38] [39]. 
Prominent intestinal mucosal damage is a theme throughout the literature surrounding CID. Toxicity to the 
rapidly dividing crypt cells of the intestinal epithelium coupled with destruction and depletion of intestinal en-
zymes is believed to be a major contributor to the decrease in absorption and increase in fluid secretion seen in 
CID [30]-[34] [40]. Direct harm to the villi and mature cells of the intestinal wall results in a higher proportion 
of immature secretory cells, this increase in secretion and decrease in absorptive capacity of the villi alters the 
osmotic gradient within the gut contributing to the onset of diarrhoea [41]. The osmotic component is believed 
to be attributable to cytotoxic agent-induced damage to colonic crypts, thereby reducing chloride absorption and 
causing water to be released into the intestinal lumen [41]. Chemotherapy-induced disturbance to intestinal ab-
sorptive capacity causes an increase in solutes within the intestinal lumen; this triggers an osmotic shift of water 
into the lumen resulting in osmotic diarrhoea [30] [34] [41]. When non-absorbable compounds are retained 
within the lumen, active transport of water and electrons is initiated to maintain luminal potential as well as to 
flush foreign matter from the gastrointestinal tract. Coupled with this, inflammation throughout the intestines 
leads to secretion of factors such as prostaglandins, leukotrienes and cytokines further stimulating secretion and 
increasing damage to the epithelium and disrupting intestinal water and ion transport resulting in hypersecretion 
[34] [40]. It is has been suggested that acute diarrhoea experienced 24 - 96 hours post-chemotherapeutic infusion 
is primarily secretory [32]. However, whether all chemotherapy-induced diarrhoeas are due to changes in 
epithelial surface area unknown. Damage to the enteric nervous system caused by chemotherapeutic treatments 
[42] [43] might underlie gastrointestinal secretory and motility disturbances involved in pathophysiology of CID. 
It is also unclear whether different chemotherapeutic regimens are associated with different types of diarrhoea. 
Moreover, the pathophysiological mechanisms underlying chronic diarrhoea persisting long after the chemo-
therapy have not been investigated. 
Although the likelihood of CID is typically unpredictable, occurrence of CID has been linked to a variety of 
patient and treatment-associated risk factors (Table 3). It has been found that age >65, gender and low perform-
ance status are common patient-associated risk factors as well as associated bowel pathologies and genetic 
polymorphisms that may affect drug metabolism [34]. Accompanying this, certain chemotherapeutic drugs and 
administration regimes have been found to increase susceptibility to CID. Most prominently the addition of 
5-FU and leucovorin to treatments, and combination of 5-FU with irinotecan and oxaliplatin increase both se-
verity and prevalence of CID [43] [44]. 
 
Table 2. Common terminology criteria for diarrhoea [36]. 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Diarrhoea 
Increase of <4 
stools per day 
over baseline. 
Increase of 4 - 6 
stools per day 
over baseline. 
Increase of >7 stools per day 
over baseline. Incontinence. 
Hospitalization. 
Life threatening 
consequences. Urgent 
intervention indicated. 
Death 
R. M. McQuade et al. 
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Table 3. Risk factors for chemotherapy-induced diarrhoea (modified from [34] [45]-[48]). 
Patient-associated risk factors 
Elderly (>65) 
Female 
Genetic polymorphisms affecting drug metabolism and distribution such as Gilbert’s syndrome,  
Crigler-Najjar syndrome 
Biliary obstruction 
Associated bowel pathology such as inflammatory bowel disease or malabsorption 
Treatment-associated risk factors 
Irinotecan & 5-FU 
Weekly chemotherapy schedule 
Infusional chemotherapy 
Bolus 5-FU 
Prior history of CID 
Prior or concomitant radiotherapy 
3. Impact of CID 
Persistent and severe diarrhoea in combination chemotherapy-treated patients often causes malnutrition and de-
hydration leading to rapid weight loss (cachexia), fatigue, renal failure, haemorrhoids, perianal skin breakdown 
[49] [50]. In some cases, chemotherapy causes severe intestinal inflammation, bowel wall thickening and ul-
ceration [51]. Thus, CID is a key contributor to the interruptions in optimal clinical outcomes and may lead to 
life-threatening sequelae [22] [23] [32]. 
CID is the primary contributor to approximately 60% of treatment alterations, with about 22% of patients re-
ceiving dose reductions, 28% of patients having dose delays and complete cessation of treatment in approxi-
mately 15% of patients due to severe diarrhoea during the course of treatment [48] [52]. A direct correlation 
between cumulative dose and severity of CID has been recognised, with high dose regimens associated with 
higher reported incidence of CID [20] [29]. Early death rates, occurring in approximately 5% of patients under-
going anti-cancer treatment, are primarily due to CID leading to severe dehydration [23]. 
About 53% of anti-CRC treated patients that receive adjuvant therapies experience grade 3 or 4 CID at some 
point during the course of treatment and current guidelines recommend aggressive treatment and hospitalization 
[53]. Thus, CID is fast becoming a major drain on healthcare resources. A recent cost of illness analysis on the 
economic impact of grade 3 - 4 CID revealed a median hospital stay of 8 days, indicating that CID is a debilitat-
ing and costly complication of CRC chemotherapy [48]. The incidence of chronic post-treatment diarrhoea 
amongst cancer survivors varies from 14% to 49% and episodes of diarrhoea can persist for more than 10 years 
[54] greatly effecting long-term quality of life. 
Long-term psychological effects of treatment-related chronic persistent diarrhoea are rarely recognised. Men-
tal and social health of CID sufferers has been shown to be greatly compromised with known psychological ef-
fects of uncontrolled CID including anxiety, depression, social isolation and low self-esteem [55]. More than 30% 
of CID sufferers experience interference to their daily activities [32]. 
4. Treatment of CID 
Current management of CID is based heavily on the nature and progression of the diarrhoea itself. CID may be 
classified as complicated or uncomplicated, late or early onset and categorised as persistent or non-persistent 
depending on the National Cancer Institute’s (2009) Common Terminology Criteria for Adverse Effects grading 
system [32] [36]. 
Uncomplicated CID can be managed through diet modification and standard dose of recommended drugs 
such as loperamide, octreotide and tincture of opium in an outpatient setting, however, complicated diarrhoea 
requires aggressive treatment and hospitalisation where patients are recommended to take anti-diarrhoeal drugs 
and intravenous fluids [34]. 
R. M. McQuade et al. 
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The recommendations of a consensus conference on the management of CID were published in 1998 and up-
dated in 2004 [40] [45]. These publications provide guidelines for evaluation and classification of symptoms of 
CID (Figure 1). Opioid derivatives loperamide and deodorized tincture of opium (DTO), and octreotide are the 
only drugs recommended in the updated treatment guidelines, due to lack of efficacy and insufficient evidence 
for benefits of other therapeutic approaches such as prophylactic treatments [22]. Although the National Cancer 
Institute’s Common Terminology Criteria for Adverse Effects grading system has been updated on several occa-
sions, CID management and treatment guidelines have not been changed since 2004. A consensus working 
statement published in 2007 offered several clinical recommendations and improvement; however no changes to 
the treatment of CID have been made [35]. 
 
 EVALUATE 
• Obtain history and duration of diarrhoea 
• Describe number of stool and stool composition (eg. 
watery, blood in stool etc.) 
• Assess patient for fever, dizziness, abdominal 
pain/cramping or weakness  
• Medication profile (ie, identify diarrheogenic agents) 
• Dietary profile (ie, identify diarrhoea enhancing foods) 
COMPLICATED 
Grade 3-4 diarrhoea or grade 1-2 
with one or more complicating 
signs or symptoms: 
• Cramping 
• Nausea 
• Vomiting 
• Decreased performance 
status 
• Fever 
• Sepsis 
• Neutropenia 
• Frank bleeding 
• Dehydration 
UNCOMPLICATED 
National Cancer Institute 
(NCI) grade 1-2 diarrhoea with 
no complicating signs or 
symptoms 
ADDED RISK FACTORS 
MANAGEMENT 
• Stop all lactose-containing products 
• Drink 8-10  large glasses of clear liquids a day 
• Eat frequent small meals  
• Instruct patient to record the number of stools and 
report symptoms of life threatening sequelae  
• For grade 2 diarrhoea, hold cytotoxic chemotherapy 
until symptoms resolve and consider dose reduction 
TREATMENT 
• Administer standard dose of loperamide 
• Consider clinical trial 
Reassess 12-24 hours later 
DIARRHOEA RESOLVING 
• Continue instructions for dietary modification 
• Gradually add solid food to diet 
• Discontinue loperamide after 12 hours diarrhoea-free 
period 
• Radiotherapy-induced diarrhoea - continue 
loperamide or other oral agent; no workup required  
DIARRHOEA RESOLVING 
• Continue instructions for dietary modification 
• Gradually add solid food to diet 
• Discontinue loperamide after 12 hours diarrhoea-free 
period 
Persistent diarrhoea (NCI grades 1-2 with no fever, 
dehydration, neutropenia, and/or blood in stool) 
EVALUATE IN OUTPATIENT SETTING 
• Check stool workup 
• Check complete blood count and electrolytes  
• Perform abdominal exam 
• Replace fluids and electrolytes as appropriate  
• Discontinue loperamide use and begin second-line 
agent 
   - Octreotide  
   - Deodorised tincture of opium 
• Radiotherapy-induced diarrhoea - continue loperamide 
or other oral agent; no workup required 
Diarrhoea Unresolved 
Progression to severe diarrhoea 
(NCI grade 3-4 with or without 
fever, dehydration, neutropenia 
and /or blood in stool) 
Progression to severe diarrhoea 
(NCI grade 3-4 with or without 
fever, dehydration, neutropenia 
and /or blood in stool) 
ADMIT TO HOSPITAL 
• Administer octreotide 
• Start intravenous fluids 
• Discontinue cytotoxic chemotherapy 
until all symptoms have resolved, 
restart chemotherapy at reduced 
dose 
PERSISTENT DIARRHOEA 
• Administer loperamide every 2 
hours 
• Start oral antibiotics 
• Observe patient for response 
Reassess 12-24 hours later 
Diarrhoea Unresolved 
 
Figure 1. Guidelines for treatment of chemotherapy-induced diarrhoea (modified from [22] [32]). 
R. M. McQuade et al. 
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Until recently the significance of chemotherapy-induced diarrhoea and its impact on regimen designation and 
treatment efficiency has been greatly underestimated. As a result current treatments available are limited and 
carry a wide variety of adverse effects including further gastrointestinal symptoms (Table 4). 
5. National Cancer Institute Guideline-Based Treatment for CID 
5.1. Loperamide 
Loperamide is a non-analgesic agonist that decreases intestinal motility through an action at µ-opioid receptors 
of the myenteric plexus [32]. High dose loperamide alleviates diarrhoea associated with chemotherapeutic ad-
ministration and is the standard first line therapy for CID [22]. However, it is associated with high levels of re-
sistance and failure, specifically when used with irinotecan, and has a variety of side-effects including severe 
constipation, abdominal pain, dizziness, and rashes and worsening of already present bloating, nausea and vom-
iting [32] [56]. Clinical studies have also reported incidents of paralytic ileus, in association with abdominal 
distension occurring in patients administered a very high dose of loperamide [34] [57]. 
5.2. Octreotide 
Loperamide-refractory and complicated diarrhoea are both treated with octreotide [22], an indirect anti-motility 
substance. Octreotide is a synthetic somatostatin analogue that inhibits specific gut hormones to increase intes-
tinal transit time promoting absorption [38] [49] [58] as well as hyperpolarizing secretomotor neurons within the 
enteric nervous system to inhibit secretion and promote net absorption [58]. Octreotide has shown to be effective 
in decreasing CID in clinical trials [38]. However severe adverse effects such as slow and/or uneven heartbeat, 
severe constipation, severe stomach pain, enlarged thyroid, vomiting, nausea, headache and dizziness occur in 
more than 10% of patients treated with octreotide [59]. Octreotide is generally reserved as a second line treat-
ment for patients who are unresponsive to loperamide after 48 hours, despite loperamide escalation [32]. 
5.3. Deodorised Tincture of Opium 
Deodorized tincture of opium (DTO) similarly to loperamide, works by activating µ-opioid receptors within the  
 
Table 4. Current treatments and their side-effects for chemotherapy-induced diarrhoea. 
Treatment Mechanism Side-Effects References 
Loperamide 
Synthetic opiate derivative μ-opioid receptor 
agonist that slows intestinal peristalsis, increases 
intestinal transit time to promote fluid  
reabsorption. Also exhibits anti-secretory 
effects through inhibition of thromboxane-A2. 
Stomach pain and bloating, ongoing or worsening 
of diarrhoea, watery and bloody diarrhoea, severe  
skin reactions (blistering and peeling), nausea, 
vomiting, dizziness, drowsiness, severe 
constipation and paralytic ileus. 
[32] [34] 
[38] [47] 
[56] [80] 
Octreotide 
Synthetically engineered somatostatin analogue  
designed to bind to somatostatin receptors; 
inhibits adenylyl cyclase to reduce secretion of 
pancreatic and intestinal hormones, increases 
intestinal transit time and promotes  
reabsorption. 
Easy bruising and unusual bleeding (nose,  
mouth, vagina and rectum), purple/red 
pinpoint spots under skin, slow and/or uneven 
heart beats, severe constipation, severe stomach 
pain, enlarged thyroid, vomiting, nausea, 
headache and dizziness. 
[22] [32]  
[38] [47] 
[48] [59]  
[80] 
Tincture  
of opium 
Similar to loperamide, acts by activating  
μ-opioid receptors to slow intestinal peristalsis  
thereby increasing intestinal transit time and 
promoting fluid reabsorption. 
Vomiting, nausea and light headedness,  
stomach/abdominal pain, painful/difficult 
urination, seizures, itching and swelling of 
the face, tongue and throat, psychological  
dependence, physical dependence, miosis 
and respiratory depression. 
[22] [34] 
Budesonide 
Orally administered synthetic steroid with  
anti-inflammatory effects. Helps to restore 
mucosal function and improve intestinal fluid 
reabsorption. Has inhibitory effect on mucosal 
prostaglandins. 
Increased blood pressure, headache, thinning 
of the skin, easy bruising, muscle pain, stomach 
pain, indigestion, mild skin rash, changes to 
menstrual cycle. 
[46] [61] 
[63] 
Atropine 
Competitive antagonist at muscarinic 
receptors. Helps to suppress the cholinergic 
effects of irinotecan. 
Allergic reactions (swelling of the lips, tongue and  
face), irregular or fast heart rate, rash or flushing, eye 
pain, headache, dizziness, blurred vision, bloating,  
nausea, heartburn, constipation, weakness, difficulty 
urinating. 
[60]-[62] 
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gastrointestinal tract to slow intestinal peristalsis, thereby increasing intestinal transit time and promoting fluid 
reabsorption [34]. Currently there are no studies demonstrating the efficacy of DTO in treatment of CID, but it is 
still a widely used anti-diarrheal drug and may be considered as a second-line therapy for persistent and uncom-
plicated diarrhoea [34]. DTO contains 10 mg/ml of morphine, making it one of the most potent forms of orally 
administered morphine available by prescription. Side-effects of DTO range from euphoria or dysphoria to 
vomiting, nausea, light headedness, stomach/abdominal pain, painful/difficult urination as well as seizures, 
itching and swelling of the face, tongue and throat. DTO has also been linked to psychological and physical de-
pendence, meiosis and respiratory depression [22] [34]. 
6. Prophylactic Measures 
6.1. Atropine 
Atropine is a competitive antagonist at muscarinic receptors that helps to suppress the cholinergic effects of 
secretory diarrhoea. Atropine functions by inhibiting the muscarinic actions of acetylcholine released by cho-
linergic nerve fibres innervating gastrointestinal smooth muscles, as well as inhibiting the actions of cholinergic 
secretomotor neurons innervating the mucosa. Dosage ranges from 0.25 - 1 mg and can be delivered intrave-
nously or subcutaneously as either prophylaxis or treatment for CID, to a maximum cumulative dose of 1.2 mg 
[60]. It has been found that subcutaneous administration of atropine prior to chemotherapeutic treatment was ef-
fective at reducing CID [60] [61]. However atropine administration is linked to swelling of the lips, tongue and 
face, irregular or fast heart rate, rash or flushing, eye pain, headache, dizziness, blurred vision, bloating, nausea, 
heartburn, constipation, weakness, difficulty urinating [60]-[62]. 
6.2. Budesonide 
Budesonide is an orally administered synthetic steroid with anti-inflammatory effects, commonly used in pa-
tients with inflammatory bowel disease. It works to restore mucosal function and improve intestinal fluid reab-
sorption as well as having an inhibitory effect on mucosal prostaglandins. Suppression of inflammation 
throughout the bowel could potentially contribute to reductions in the occurrence of CID; however published 
data revealed no significant decreases in incidence of CID from concurrent budesonide and loperamide treat-
ment [63]. Furthermore budesonide has been linked to increased blood pressure, headache, thinning of the skin, 
easy bruising, muscle pain, stomach pain, indigestion, mild skin rash, and changes to menstrual cycle [46] [61] 
[63]. 
6.3. Antibiotics 
Several studies have investigated the effectiveness of antibiotic therapy to combat irinotecan-induced diarrhoea 
[64]. Results surrounding antibiotic use in irinotecan-induced diarrhoea remain controversial. Several studies in-
dicated that elimination of β-glucoronidase producing microflora through the use of antibiotics namely penicillin, 
streptomycin, cefixime, ceftriaxone, neomycin and levofloxacin may decrease incidence and severity of CID 
[65]-[67]. In contrary, non-significant reductions in severity and frequency of diarrhoea accompanied by sub-
stantially higher rates of grade 2 diarrhoea were found [68]. Moreover, contention over the use of antibiotics in 
immune compromised patients for risk of Clostridium difficile (C. difficile) infection causing both nosocomial 
and antibiotic-associated diarrhoea is evident throughout literature [46] [65] [69]. C. difficile is a prominent and 
potentially life threatening infection that results from disturbance of normal bacterial flora in the colon, trigger-
ing release of toxins that cause mucosal inflammation and damage. C. difficile infection is most frequent 
amongst hospitalized patients and it is well known that colorectal cancer, abdominal surgery, as well as a weak-
ened immune system as a result of chemotherapy, increases susceptibility to C. difficile infection [70] [71]. 
6.4. Glutamine 
Glutamine is an amino acid found within the gastrointestinal tract, it acts as a major energy source for entero-
cytes as well as playing an important role in gut integrity and immune responses [72]. It is believed that gluta-
mine can stimulate intestinal mucosa growth, and therefore may reduce gastrointestinal toxicity [32] [73] [74]. 
Several studies over the last decade have investigated the incidence and severity of CID in patients receiving 
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prophylactic oral and intravenous glutamine [75]-[79]. It was reported that intravenous administration of 20 g 
glutamine reduced plasma endotoxin levels and decreased severity of CID [77]. However a more recently con-
ducted meta-analysis concluded that, although glutamine may reduce the duration of CID, it does not reduce its 
severity [78]. Furthermore, a trial involving high-dose chemotherapy and glutamine-containing intravenous so-
lutions showed significantly higher incidence of relapse and death in patients receiving glutamine [79]. 
7. Emerging & Potential Treatments for CID 
Given that current treatments for CID have limited efficacy and a wide range of adverse effects, the search for 
and use of alternative anti-diarrhoeal agents with few or no side-effects is essential. Several emerging and al-
ready existing treatments for other conditions associated with acute and chronic diarrhoea, such as irritable 
bowel syndrome (IBS), travellers’ diarrhoea and other conditions could be considered and tested for the treat-
ment of CID. 
7.1. Adsorbents 
Adsorbent substances are emerging as promising avenues in the treatment of CID. Adsorbents work by collect-
ing excess materials on their surface and transporting them through the excretion process. Activated charcoal 
has long been used in the treatment of acute poisoning and is under investigation as a remedy for the late onset 
diarrhoea experienced after 5-FU and irinotecan infusions [81]. AST-120 also known as kremazin, a car-
bon-based adsorbent that is believed to absorb uremic toxins, such as indoxyl sulphate, in the gut has been ex-
plored in both cancer patients with irinotecan-induced diarrhoea and nonconstipated IBS sufferers [82] [83]. 
AST-120 has been found to be safe and well-tolerated, effective in reducing pain and bloating in nonconstipated 
IBS sufferers and to ameliorate irinotecan-induced diarrhoea without disrupting clearance of irinotecan metabo-
lites. 
7.2. Chloride Channel Inhibitors 
Chloride is an essential ion in intestinal secretion and absorption. Secretory diarrhoea, such as that experienced 
in irinotecan-treated patients, results from a combination of excessive secretion and reduced absorption in the 
intestinal lumen [84] [85]. Excessive fluid secretion is driven by active chloride secretion, followed by secon-
dary movement of water and sodium into the intestine. Deliberate inhibition of calcium-activated chloride 
channels located on enterocytes throughout the intestines reduces excretion of chloride into the intestinal lumen 
and consequently decreases the presence of water and sodium, diminishing the symptoms of diarrhoea [86]. 
7.3. Kappa Opioid Receptor Agonists 
Opioid receptors (µ (mu), δ (delta) and κ (kappa)) located throughout the peripheral and central nervous systems 
participate in inhibition of perception of noxious stimuli from the gastrointestinal tract [87]. Although effective 
as anti-diarrhoeal agents both µ and δ agonists have many adverse effects such as constipation and opioid de-
pendence, which impede their general use in clinical practice [87]. However, κ-opioid receptor agonists seem to 
be devoid of these symptoms. 
Asimadoline is a highly selective and potent κ-opioid receptor agonist that is predominantly peripherally re-
stricted at doses below 5 mg [88]. In clinical trials conducted in IBS patients it displayed a significant improve-
ment in frequency/urgency of stools and pain free days and adequate relief of pain scores [89] [90]. Although 
there was no significant improvement in primary end point (number of months accrued with adequate relief of 
pain), asimadoline appeared to be well tolerated and produced overall improvement of gastrointestinal symp-
toms, including diarrhoea [90] highlighting that it could be used as a potential therapeutic for CID given that 
pain relief is not a primary concern in CID sufferers. 
7.4. Enkephalinase Inhibitors 
Enkephalins are endogenous neurotransmitters found throughout the enteric nervous system. Known to be 
pro-absorptive and anti-secretory in nature, enkephalins act on δ-opioid receptors, increasing chloride absorption 
and inhibiting adenylate cyclase to reduce intestinal secretion. Endogenous enkephalins are rapidly degraded by 
R. M. McQuade et al. 
 
 401 
enkephalinase. Inhibition of enkephalinase has recently been tested for anti-secretory effects against numerous 
secretagogues including cholera toxin and prostaglandins. Racecadotril is a powerful enkephalinase inhibitor 
with its active metabolite thiorphan being effective in clinical management of acute diarrhoea in both adults and 
children [91] [92]. Clinical trials of racecadotril have primarily been undertaken in patients with acute diarrhoea 
of presumed infectious origin and chronic HIV-related diarrhoea. Racecadotril significantly decreases mean 
stool output and duration of acute diarrhoea in both adults and infants when compared to placebo [93] [94], and 
has a similar efficacy to loperamide [91] [95] [96], but appears to be better tolerated than loperamide in both 
adults and children [97]. 
7.5. Cannabinoids 
The effects of cannabinoids are primarily mediated by cannabinoid receptors, a widely expressed class of 
G-protein coupled receptors. Currently known two receptor subtypes, CB1 and CB2, are the main constituent of 
the endocannabinoid system. Recent studies have found that endocannabinoids acting on myenteric cannabinoid 
receptors can inhibit colonic propulsion [98] [99]. Dronabinol, a non-selective cannabinoid receptor agonist in-
hibits colonic motility in healthy subjects [98] [99] and patients with IBS-related diarrhoea [100]. 
8. Conclusion 
Combination therapies now represent the standard first-line of treatment in CRC worldwide, with statistics 
showing great potential to increase overall survival in locally resected stage III CRC. Chemotherapy-induced 
gastrointestinal toxicity persists as a major contributor to dose delays, reductions and treatment terminations. 
Chemotherapy-induced diarrhoea is one of the most common disruptions in clinical management of CRC, af-
fecting a vast majority of patients being treated with combination or adjuvant therapies containing 5-FU and iri-
notecan. Current treatments for CID are limited and have an abundance of concomitant symptoms; but novel and 
emerging anti-diarrhoeal treatments may present an additional unexplored avenue of treatments for CID suffer-
ers. Ongoing investigation to identify potential targets and innovative treatment agendas to decrease chemo-
therapy-related toxicity is essential to improve clinical outcomes and quality of life amongst CID sufferers. 
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DTO: Deodorized Tincture of Opium 
FOLFIRI: Combination of 5-Fluorouracil, Irinotecan and Leucovorin. 
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